CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D058186: Acute Kidney Injury NIH

(Synonyms: Acute Kid, Acute Kidn, Acute Kidney, Acute Kidney Injury)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (43)


Name (Synonyms) Correlation
drug41 3D Telemedicine Wiki 0.28
drug65 ACT-541478 dose E1 Wiki 0.24
drug368 Blood Transfusion Wiki 0.24
drug54 ACE inhibitor, angiotensin receptor blocker Wiki 0.24
drug86 ASTX660 Wiki 0.24
drug39 38-questions questionnaire Wiki 0.24
drug60 ACT-541478 10 mg Wiki 0.24
drug94 AVIGAN 200 mg FT Wiki 0.24
drug61 ACT-541478 100 mg Wiki 0.24
drug66 ACT-541478 high or low dose (or placebo) Wiki 0.24
drug200 Any drug used to treat Covid-19 Wiki 0.24
drug907 FAVIR 200 MG FT Wiki 0.24
drug93 AVIGAN 200 MG Film Tablets Wiki 0.24
drug973 GAD-7 General anxiety disorder scale Wiki 0.24
drug62 ACT-541478 1000 mg Wiki 0.24
drug57 ACEIs Wiki 0.24
drug2148 SBI-101 Wiki 0.24
drug1313 LSALT peptide Wiki 0.24
drug88 AT-527 Wiki 0.24
drug64 ACT-541478 300 mg Wiki 0.24
drug36 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients) Wiki 0.24
drug78 ARFC mask Wiki 0.24
drug63 ACT-541478 30 mg Wiki 0.24
drug37 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients ) Wiki 0.24
drug50 ABTL0812 Wiki 0.24
drug2724 [TIMP-2]*[IGFBP-7] Wiki 0.24
drug1736 PHQ-9 Depression Scale Wiki 0.24
drug1625 Non interventional study Wiki 0.24
drug46 68Ga-DX600 PET/CT Wiki 0.24
drug1490 Midazolam Wiki 0.24
drug2041 Recombinant human alkaline phosphatase Wiki 0.24
drug958 Folfirinox Wiki 0.24
drug908 FAVIRA 200 MG Film Tablet Wiki 0.24
drug92 AV-COVID-19 Wiki 0.24
drug2729 acute kidney injury Wiki 0.24
drug87 AT-001 Wiki 0.24
drug1866 Plasma expansion with Ringer's Acetate Wiki 0.24
drug1269 Itraconazole Wiki 0.17
drug663 Conventional treatment Wiki 0.17
drug1442 Matching placebo Wiki 0.17
drug33 2D Telemedicine Wiki 0.17
drug70 AG0301-COVID19 Wiki 0.17
drug1822 Placebo Wiki 0.05

Correlated MeSH Terms (14)


Name (Synonyms) Correlation
D014947 Wounds and Injuries NIH 0.38
D007049 Iatrogenic Disease NIH 0.24
D018805 Sepsis NIH 0.22
D018746 Systemic Inflammatory Response Syndrome NIH 0.14
D009102 Multiple Organ Failure NIH 0.14
D007238 Infarction NIH 0.12
D009203 Myocardial Ischemia NIH 0.09
D013577 Syndrome NIH 0.05
D012128 Respiratory Distress Syndrome, Adult NIH 0.04
D016638 Critical Illness NIH 0.03
D018352 Coronavirus Infections NIH 0.03
D045169 Severe Acute Respiratory Syndrome NIH 0.02
D055371 Acute Lung Injury NIH 0.02
D012127 Respiratory Distress Syndrome, Newborn NIH 0.02

Correlated HPO Terms (3)


Name (Synonyms) Correlation
HP:0001919 Acute kidney injury HPO 1.00
HP:0100806 Sepsis HPO 0.22
HP:0001658 Myocardial infarction HPO 0.09

There are 17 clinical trials

Clinical Trials


1 MR-Evaluation of Renal Function In Septic Patients

A study of renal blood flow and renal oxygenation measured by magnetic resonance after a standardized fluid challenge in critically ill, resuscitated, patients with sepsis due to COVID-19 or other agents.

NCT02765191 Sepsis, Severe Acute Kidney Injury COVID-19 Other: Plasma expansion with Ringer's Acetate
MeSH:Sepsis Acute Kidney Injury
HPO:Acute kidney injury Sepsis

Primary Outcomes

Description: Measured with arterial spin labelling (ASL), Phase Contras, Blood oxygenation level dependent (BOLD) and T(2) -Relaxation-Under-Spin-Tagging (TRUST), compared to baseline measurement

Measure: Change in renal blood flow and renal oxygenation after standardized plasma expansion with fluid bolus

Time: When achieved according to protocol, approximately 3-10 minutes after intervention

Description: Measured with arterial spin labelling (ASL), Phase Contras, Blood oxygenation level dependent (BOLD) and T(2) -Relaxation-Under-Spin-Tagging (TRUST) during baseline measurement.

Measure: Descriptive renal oxygenation and blood flow in critical illness due to sepsis

Time: During Critical illness - at one time point

Description: Measured with arterial spin labelling (ASL), Phase Contras, Blood oxygenation level dependent (BOLD) and T(2) -Relaxation-Under-Spin-Tagging (TRUST) images stratified in groups in regards to KDIGO grade during exam.

Measure: Descriptive renal oxygenation and blood flow in critical illness in no/low grade AKI or high grade AKI.

Time: During Critical illness - at one time point

2 CSP #599 - Transfusion Trigger After Operations in High Cardiac Risk Patients (TOP)

The goal of the proposed study is to determine whether a liberal transfusion strategy (transfusion trigger at Hb < 10 gm/dl) in Veterans at high cardiac risk who undergo major open vascular and general surgery operations is associated with decreased risk of adverse postoperative outcomes compared to a restrictive transfusion strategy (transfusion trigger at Hb < 7 gm/dl).

NCT03229941 Myocardial Infarction Coronary Revascularization Acute Renal Failure Procedure: Blood Transfusion
MeSH:Acute Kidney Injury Myocardial Infarction Infarction
HPO:Acute kidney injury Myocardial infarction

Primary Outcomes

Description: MI will be defined using the Third Universal Definition of Myocardial Infarction. Acute renal failure will be defined as Acute Kidney Injury stage III according to RIFLE criteria. Baseline creatinine will be considered the creatinine upon admission prior to the index operation. The above urine output criteria will be only used for patients who are in the ICU and have precise monitoring of their urinary output. For patients on the surgical floor only serum creatinine changes will be used for assessment of this endpoint. Coronary revascularization will be defined as a coronary artery bypass graft, or percutaneous coronary intervention (either angioplasty or stenting). Stroke will be defined as new unilateral neurological deficit that lasts for more than 24 hours, and is confirmed by a brain imaging modality (computed tomography or magnetic resonance imaging study) demonstrating new brain infarct.

Measure: A composite endpoint of all-cause post-randomization mortality, myocardial infarction (MI), coronary revascularization, acute renal failure, or post-randomization ischemic stroke up to 90 days after randomization.

Time: 90 days after randomization

Secondary Outcomes

Description: Wound infection will be defined according to the Centers for Disease Control and Prevention (CDC) guidelines as a) positive wound culture, or b) drainage of pus from a wound, or c) suspicion of wound infection that was drained operatively. Pneumonia will be defined according to the CDC definition as chest radiograph with new or progressive infiltrate, consolidation, cavitation, or pleural effusion and any of the following: new onset of purulent sputum or change in character of sputum, or organism isolated from blood culture, trans-tracheal aspirate, bronchial brushings, or biopsy. Sepsis will be defined as a combination of two of the following systemic inflammatory response syndrome (SIRS) criteria, plus suspected or present source of infection. SIRS criteria will include the following: temperature greater than 38C, heart rate greater than 90 beats/min, WBC > 12,000 or < 4,000, or > 10% bands.

Measure: A composite endpoint of postoperative infectious complications at 90 days post-randomization: Infectious complications will include wound infections, pneumonia, and sepsis.

Time: 90 days after randomization

Description: The diagnosis of cardiac arrhythmias will be based on EKG findings. Only arrhythmias that result in initiation of new treatment regimen (to include medications, implantable devices, or surgical intervention) during hospitalization will be recorded. CHF will require at least one of the following symptoms or signs new or worsening: dyspnea at rest, orthopnea, or paroxysmal nocturnal dyspnea and radiological evidence of heart failure or worsening heart failure and increase/initiation of established treatment. Cardiac arrest will be defined as the cessation of cardiac pump function activity that results in loss of consciousness and absence of circulating blood flow as evidenced by absent carotid pulse. Only episodes of cardiac arrest that are reversed will be collected under this endpoint. If they are not reversed the event will be categorized as death.

Measure: A composite endpoint of cardiac complications (other than MI) at 90 days post-randomization: Cardiac complications will include new cardiac arrhythmias that necessitate new treatment, new or worsening congestive heart failure (CHF), and cardiac arrest no

Time: 90 days after randomization

Description: The investigators will determine vital status by telephoning participants after hospital discharge, by searching the electronic medical record and the National Death Index.

Measure: All-cause mortality at 1 year after randomization.

Time: 12 months after randomization

Description: MI, coronary revascularization, acute renal failure, or postoperative ischemic stroke.

Measure: A composite endpoint of all-cause mortality,

Time: 30 days after randomization

Description: Length of hospital stay

Measure: Length of hospital stay.

Time: At hospital discharge, up to 1 year

Other Outcomes

Description: All cause postoperative mortality, Postoperative MI, Postoperative coronary revascularization, Postoperative stroke,Postoperative acute renal failure

Measure: The investigators will examine individual rates of the outcomes that consist of individual components of the primary endpoint.

Time: 90 days after randomization

3 Adverse Events Related to Treatments Used Against Coronavirus Disease 2019

The outbreak of Covid-19 started several clinical trials and treatment experiments all over the world in the first months of 2020. This study investigates reports of adverse events related to used molecules, including but not limited to protease inhibitors (lopinavir/ritonavir), chloroquine, azithromycin, remdesivir and interferon beta-1a. Analyses of reports also include the International classification of disease ICD-10 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).

NCT04314817 Coronavirus Iatrogenic Disease Acute Kidney Injury ARDS, Human Drug: Any drug used to treat Covid-19
MeSH:Coronavirus Infections Respiratory Distress Syndrome, Adult Acute Kidney Injury Iatrogenic Disease
HPO:Acute kidney injury

Primary Outcomes

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Renal failure

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Secondary Outcomes

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Heart failure

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: EKG disturbance

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Hepatic failure

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Anemia

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Leucopenia

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Vascular disease

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Toxidermia

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Osteoarticular adverse event

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Death

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Acute respiratory distress syndrome

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms

Measure: Pulmonary embolism or pulmonary hypertension

Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020

4 Acute Kidney Injury in Patients Hospitalized With COVID-19 in Wuhan, China: a Single-center Retrospective Observational Study

The kidney may be affected in coronavirus-2019 disease (COVID-19). This study assessed the predictors and outcomes of acute kidney injury (AKI) among individuals with COVID-19.

NCT04316299 COVID-19 Acute Kidney Injury Kidney Function
MeSH:Acute Kidney Injury Wounds and Injuries
HPO:Acute kidney injury

Primary Outcomes

Description: the incidence of Acute Kidney Injury

Measure: Rate of Acute Kidney Injury

Time: From date of admission until the date of discharge or death from any cause, up to 60 days

Secondary Outcomes

Description: death from any cause in the hospital

Measure: Rate of Death

Time: From date of admission until the date of death from any cause, up to 60 days

Description: days from admission to discharge or death

Measure: the length of hospital stay

Time: From date of admission until the date of discharge or death from any cause, up to 60 days

5 Uppsala Intensive Care Study of Mechanisms for Organ Dysfunction in Covid-19

The study aims to investigate organ dysfunction and biomarkers in patients with suspected or verified COVID-19 during intensive care at Uppsala University Hospital.

NCT04316884 COVID-19 Organ Dysfunction Syndrome Sepsis Organ Dysfunction Syndrome, Multiple Septic Shock Acute Kidney Injury Acute Respiratory Distress Syndrome
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Acute Kidney Injury Syndrome Systemic Inflammatory Response Syndrome Multiple Organ Failure
HPO:Acute kidney injury

Primary Outcomes

Description: KDIGO AKI score

Measure: Acute Kidney Injury

Time: During Intensive Care, an estimated average of 10 days.

Secondary Outcomes

Description: Acute Respiratory Distress Syndrome yes/no

Measure: ARDS

Time: During intensive care, an estimated average of 10 days.

Description: Death within 30 days of ICU admission

Measure: 30 day mortality

Time: 30 days

Description: Death within 1 year of ICU admission

Measure: 1 year mortality

Time: 1 year

Description: Development of Chronic Kidney Disease

Measure: Chronic Kidney Disease

Time: 60 days and 1 year after ICU admission

Description: Sequential Organ Failure Score as a continuous variable

Measure: SOFA-score

Time: During Intensive Care, an estimated average of 10 days.

6 Renal Outcome in Patients With Coronavirus Disease 2019 (COVID-19)

Acute kidney injury (AKI) is reported to occur in 0.5-9% of severe acute respiratory distress coronavirus 2-positive patients and AKI has been identified as an independent risk factor for in-hospital mortality. The present study aims to investigate the incidence of renal outcome of in-hospital patients diagnosed with COVID-19.

NCT04353583 Acute Kidney Injury Corona Virus Infection
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Acute Kidney Injury
HPO:Acute kidney injury

Primary Outcomes

Description: As determined by Kidney Disease: Improving Global Outcomes (KDIGO) criteria

Measure: Incidence of AKI

Time: Within 7 days after admission

Secondary Outcomes

Description: Serial biomarker assessment

Measure: Renal function changes during hospital stay

Time: from hospital admission til discharge up to 3 months

Description: As determined by KDIGO criteria

Measure: Incidence of chronic kidney disease

Time: 3 months post-hospital admission

7 The Role of Noncoding RNAs in COVID-19 and COVID-19 Associated Acute Kidney Injury (MiRCOVID)

In this study, critically ill patients with highly suspected or confirmed COVID-19 will be included. Main goal is the identification of noncoding RNAs in COVID-19 associated organ dysfunction with an emphasis on acute kidney injury.

NCT04381351 COVID-19
MeSH:Acute Kidney Injury
HPO:Acute kidney injury

Primary Outcomes

Measure: predicitive value of noncoding RNAs in COVID-19 associated organ dysfunction

Time: 12 months

8 Urinary Biomarkers (TIMP-2 and IGFBP7) for Early Diagnostic Assessment of Acute Kidney Injury in Patients With SARS-CoV-2 (COVID-19)

Among patients with SARS-CoV-2 pneumonia, approximately 20% have an acute kidney injury (AKI) and 5% require renal replacement therapy. Occurrence of AKI in patients with COVID-19 is associated with increased morbidity and mortality. Early detection of patients at risk of AKI would allow to prevent onset or worsening of AKI. The aim of this study is to determine if urine biomarkers of renal tubular damage such as TIMP-2 and IGFBP7 could early identify patients with SARS-CoV-2 pneumonia at risk of developing AKI.

NCT04393428 COVID-19 Renal Replacement Therapy Acute Kidney Injury Other: [TIMP-2]*[IGFBP-7]
MeSH:Acute Kidney Injury
HPO:Acute kidney injury

Primary Outcomes

Description: Sensibility and specificity of urinary [TIMP-2]*[IGFBP-7] > 0,3 to predict AKI (KDIGO stage ≥ 1) in SARS-CoV-2 patients at day-7 after measurement

Measure: Sensibility and specificity of urinary

Time: Occurence of AKI 7 days after urinary biomarkers measurement

Secondary Outcomes

Description: Sensibility and specificity of urinary [TIMP-2]*[IGFBP-7] > 0,3 to predict AKI worsening, renal replacement therapy requirement or persistant AKI

Measure: Sensibility and specificity of urinary

Time: Occurnce of AKI worsening, renal replacement therapy requirement or persistant AKI, 7 days after urinary biomarkers mesurement

9 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of LSALT Peptide as Prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

To evaluate the proportion of subjects alive and free of respiratory failure (e.g. need for non-invasive or invasive mechanical ventilation, high flow oxygen, or ECMO) and free of the need for continued renal replacement therapy (RRT) on Day 28. The need for continued RRT at Day 28 will be defined as either dialysis in the past 3 days (Day 26, 27, or 28) or an eGFR on Day 28 <10 mL/min/1.73 m2.

NCT04402957 COVID Severe Acute Respiratory Syndrome Sars-CoV2 Acute Kidney Injury Drug: LSALT peptide Drug: Placebo
MeSH:Severe Acute Respiratory Syndrome Coronavirus Infections Acute Kidney Injury Syndrome Wounds and Injuries
HPO:Acute kidney injury

Primary Outcomes

Description: To evaluate the efficacy of intravenous LSALT peptide plus standard of care to prevent the progression of COVID-19 to mild, moderate or severe ARDS, acute kidney injury, cardiomyopathy, acute liver injury, coagulopathy, or death in patients infected with SARS-CoV-2 compared with placebo plus standard of care.

Measure: Development of Acute Respiratory Distress Syndrome (ARDS) and Other Organ Injuries

Time: 28 days

Secondary Outcomes

Description: High-frequency oscillatory ventilation, with its rapid delivery of low tidal volumes and a respiratory rate in the range of 60 to 900 breaths/minute, has also been utilized in ARDS patients.

Measure: Ventilation-free days

Time: 28 days

Description: Oxygen therapy provided as non-invasive therapy for ARDS patients.

Measure: Time on nasal cannula or oxygen masks

Time: 28 days

Description: 28 day mortality - all cause and attributable

Measure: 28 day mortality - all cause and attributable

Time: 28 days

Description: ICU and hospitalization length of stay (days)

Measure: ICU and hospitalization length of stay (days)

Time: 28 days

Description: Swab (nasopharyngeal, nasal, throat, sputum, or lower respiratory tract) at baseline (Day 1) and every 3 days thereafter until eradication → virologic clearance rate

Measure: SARS-CoV2 testing

Time: 28 days

Description: Extracorporeal membrane oxygenation (ECMO) is often used for severe ARDS to allow lung healing/repair and reverse respiratory failure.

Measure: Need and duration for extracorporeal membrane oxygenation (ECMO)

Time: 28 days

Description: Vasopressor free days

Measure: Vasopressor free days

Time: 28 days

Description: Chest X-rays performed at Baseline, Day 3, at clinical improvement, and end-of-treatment (EOT) and study (EOS) to determine presence of bilateral opacities.

Measure: Radiographic pulmonary assessments

Time: 28 days

Description: Change in daily mMRC dyspnea and SOFA scores (0 to 4) with 4 being the most severe outcome

Measure: Change in modified Medical Research Council (mMRC) dyspnea and Sequential Organ Failure Assessment (SOFA) scores

Time: 28 days

Description: Incidence of other organ (non-lung) disorders

Measure: Incidence of non-lung disorders

Time: 28 days

Description: Change in liver function tests (ALT, AST, and total bilirubin levels) from baseline

Measure: Measures of liver dysfunction

Time: 28 days

Description: Change in SCr and eGFR from baseline

Measure: Measures of kidney dysfunction

Time: 28 days

Description: Change in highly-sensitive troponin (hs-troponin) from baseline

Measure: Measures of cardiac dysfunction

Time: 28 days

Description: Change from baseline ACT, aPTT, and/or PT/INR levels

Measure: Measures of coagulopathies

Time: 28 days

Description: Change in baseline antiviral immunoglobulins (IgG, IgM) at EOS.

Measure: Changes in immunogenic responses

Time: 28 days

Description: Changes in total healthcare costs from admission to discharge between treatment groups.

Measure: Healthcare outcomes

Time: 28 days

Description: Change in serum cytokines including IL-1α, IL-1ß, IL-1ra, IL-5, IL-6, IL-8, IL-12, TNFα, CXCL10/IP10, MCP-3, and ferritin drawn at the same time as LSALT peptide levels

Measure: Molecular changes in pro-inflammatory pathways

Time: 28 days

Description: Pharmacokinetics of LSALT peptide over the study period.

Measure: Pharmacokinetics of LSALT peptide

Time: 28 days

10 Prediction of Acute Kidney Injury in Patients With COVID-19 Associated Acute Respiratory Distress Syndrome

The two biomarkers determined in urine, "Tissue Inhibitor of Metalloproteinases 2 (TIMP-2)" and "Insulin-like Growth Factor-Binding Protein 7 (IGFBP7)", can indicate the occurrence of Acute kidney injury (AKI) in cardiac surgery and critically ill patients at an early stage. However, no data are available whether these parameters can also predict the occurrence of AKI in the context of COVID-19 infection. An early prediction of AKI can be helpful for the optimisation of therapeutic management to improve patient outcome and for the triage of patients. The aim of this observational study is to evaluate whether the biomarker [TIMP- 2]*[IGFBP7] can predict the occurrence of AKI in critically ill patients suffering from SARS-CoV2 associated acute respiratory distress syndrome.

NCT04406688 Acute Kidney Injury COVID-19 ARDS
MeSH:Acute Kidney Injury Wounds and Injuries
HPO:Acute kidney injury

Primary Outcomes

Description: Occurence of moderate or severe AKI

Measure: Occurence of acute kidney injury (AKI)

Time: within 7 days after beginning of moderate or severe ARDS

Secondary Outcomes

Measure: Occurence of transient and persistent AKI

Time: within 7 days after beginning of moderate or severe ARDS

Measure: Occurence of Renal replacement therapy during hospital stay

Time: up to 4 weeks after beginning of moderate or severe ARDS

Measure: Duration of renal replacement therapy

Time: up to 4 weeks after beginning of moderate or severe ARDS

Measure: Mortality

Time: up to 4 weeks after beginning of moderate or severe ARDS

Measure: Duration of mechanical ventilation

Time: up to 4 weeks after beginning of moderate or severe ARDS

Measure: Duration of vasopressor administration

Time: up to 4 weeks after beginning of moderate or severe ARDS

Measure: ICU length of stay

Time: up to 4 weeks after beginning of moderate or severe ARDS

Measure: Hospital length of stay

Time: up to 4 weeks after beginning of moderate or severe ARDS

Other Outcomes

Description: e.g., Analysis of interleukin (IL) 6, IL8

Measure: Add-on analysis: pro- and antiinflammatory mediators

Time: within 7 days after beginning of moderate or severe ARDS

11 Acute Kidney Injury In Corona Virus Infection Disease (COVID19) in United Kingdom

Severe Acute respiratory syndrome coronovirus (SARS-CoV-2) was first described in Wuhan in December 2019. It quickly spread to rest of the world and was declared pandemic by World health organisation. Initial case series focused on lung involvement in the form alveolar haemorrhages and respiratory failure. However, subsequently, there have been reports of kidney involvement resulting in severe acute kidney injury. However, the reported incidence from Chinese data has been less than 5% and detailed epidemiology of AKI in COVID-19 disease is lacking.

NCT04407156 COVID AKI Other: acute kidney injury
MeSH:Acute Kidney Injury
HPO:Acute kidney injury

Primary Outcomes

Description: This is the proportion of patients with Acute kidney injury in COVID-19

Measure: Incidence of Acute kidney injury in COVID-19

Time: 7 days

Secondary Outcomes

Description: This is the number of deaths in COVID-19 AKI patients

Measure: All-cause mortality in AKI patients

Time: 7 days

12 AKI Biomarkers for Prediction of Acute Kidney Injury in Critically Ill Patients With COVID-19 and Respiratory Disease

This research aims to investigate the role of daily measurement of urinary cell cycle arrest markers and other serum and urinary biomarkers to predict the development of acute kidney injury in critically ill patients with COVID-19 and acute respiratory disease.

NCT04408248 COVID Acute Respiratory Failure Acute Kidney Injury
MeSH:Respiratory Insufficiency Acute Kidney Injury
HPO:Acute kidney injury

Primary Outcomes

Description: As defined by Kidney Diseases: Improving Global Outcome

Measure: Any stage of acute kidney injury

Time: 7 days

Secondary Outcomes

Description: Renal replacement therapy requirement at the clinicians' discretion

Measure: need for RRT in first 7 days

Time: 7 days

Description: ICU mortality

Measure: Mortality

Time: 7 and 28 days

Description: Duration

Measure: Duration of mechanical ventilation

Time: 7 and 28 days

Description: Duration

Measure: Duration of vasopressor support

Time: 7 and 28 days

13 A DB, Placebo-Controlled, Two-Arm Parallel-Group, Phase 3 RCT to Investigate the Efficacy and Safety of Recombinant Human Alkaline Phosphatase for Treatment of Patients With SA-AKI

Clinical phase 3 study to investigate the effect of recAP on 28 day mortality in patients admitted to the ICU with acute kidney injury that is caused by sepsis. 1400 patients will be included in the study that is conducted in approx. 100 ICU's in Europe and North America There are two arms in the study, one with active treatment and one with an inactive compound (placebo). Treatment is by 1 hour intravenous infusion, for three days. Patients are followed up for 28 days to see if there is an improvement on mortality, and followed for 90 and 180 days for mortality and other outcomes e.g. long-term kidney function and quality of life.

NCT04411472 Acute Kidney Injury Due to Sepsis Biological: Recombinant human alkaline phosphatase Other: Placebo
MeSH:Sepsis Acute Kidney Injury
HPO:Acute kidney injury Sepsis

Primary Outcomes

Description: To demonstrate an effect of recAP on 28 day all cause mortality

Measure: 28-day all-cause mortality

Time: 28 days

Secondary Outcomes

Description: MAKE 90: dead or on RRT or ≥25% decline in estimated glomerular filtration rate (eGFR) on Day 90 relative to the known or assumed pre-AKI reference level.

Measure: To investigate the effect of recAP on long-term Major Adverse Kidney Events (MAKE).

Time: 90 Days

Description: Days alive and free of organ support through Day 28, i.e., days alive with no MV, RRT, vasopressors or inotropes (with death within 28 days counting as zero days).

Measure: To investigate the effect of recAP on use of organ support, i.e., mechanical ventilation (MV), Renal Replacement Therapy (RRT), vasopressors or inotropes.

Time: 28 days

Description: Days alive and out of the ICU through Day 28 (with death within 28 days counting as zero days).

Measure: To investigate the effect of recAP on length of stay (LOS) in ICU.

Time: 28 days

Description: Time to death through Day 90.

Measure: To investigate the effect of recAP on 90-day allcause mortality

Time: 90 days

14 A Multi-center, Randomized, Case Controlled, Double-blind, Ascending-dose Study of Extracorporeal Mesenchymal Stromal Cell Therapy (SBI-101 Therapy) in COVID-19 Subjects With Acute Kidney Injury Receiving Renal Replacement Therapy

The purpose of this study is to assess the safety and tolerability of the investigational product, SBI-101, in COVID-19 subjects with Acute Kidney Injury (AKI). SBI-101 is a biologic/device combination product designed to regulate inflammation and promote repair of injured tissue using allogeneic human mesenchymal stromal cells. SBI-101 will be integrated into the renal replacement circuit and patients will be treated for up to 24 hours.

NCT04445220 COVID-19 Acute Kidney Injury Biological: SBI-101
MeSH:Acute Kidney Injury Wounds and Injuries
HPO:Acute kidney injury

Primary Outcomes

Measure: Safety and tolerability as measured by incidence of IP-related serious adverse events

Time: Outcomes and Serious Adverse Events through Day 180

15 Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19 and High Risk of Acute Kidney Injury

The aim is to describe the epidemiology and determine the independent risk factors for mortality and acute organ injury in AKI and to assess the impact of different treatment strategies on survival. This will allow the development of prevention strategies and design of appropriately powered intervention studies.

NCT04445259 COVID Acute Kidney Injury Critical Illness
MeSH:Acute Kidney Injury Critical Illness Wounds and Injuries
HPO:Acute kidney injury

Primary Outcomes

Description: As defined by Kidney Diseases: Improving Global Outcomes (KDIGO) criteria

Measure: Incidence of any stage of acute kidney injury

Time: 14 days

Secondary Outcomes

Description: Mortality

Measure: Mortality

Time: 14-day, hospital, and intensive care unit (ICU) mortality

Description: Defined by return of creatinine to < 1.5 times of baseline

Measure: Renal recovery

Time: 14 days

Description: Percentage

Measure: Percentage of patients who receive renal replacement therapy

Time: 14 days

Description: Percentage of participants who are dialysis dependent

Measure: Percentage of participants who are dialysis dependent

Time: Through study completion, an average of 90 days

Description: Days without vasoactive medications and mechanical ventilation

Measure: Free-days of vasoactive medications and mechanical ventilation

Time: Day 30

Description: Length of intensive care unit and hospital stay

Measure: Length of intensive care unit and hospital stay

Time: Through study completion, an average of 90 days

Description: Congestive heart failure, Arrhythmia, Acute respiratory distress syndrome, Septic shock, Acute cardiac injury, pneumonia

Measure: Number of participants with consequences following AKI

Time: Through study completion, an average of 90 days

Description: Time from illness onset to need for mechanical ventilator support

Measure: Time from illness onset to need for mechanical ventilator support

Time: Through study completion, an average of 30 days

16 Acute Kidney Injury and Renal Outcomes for COVID-19 Patients in Intensive Care Units

The actual COVID-19 epidemy is an unprecedented healthcare problem. Although acute respiratory distress syndrome is the main organ failure, acute kidney injury (AKI) has appeared to be more frequent and more severe than expected. Some data suggested a potential direct renal tropism of the virus, or undirect injury by "cytokine storm". The aims of this study are: 1. To describe incidence, severity and mortality associated with AKI during covid-19 infection in ICU 2. To identify specific risk factors for AKI 3. To explore pathophysiologic mechanism of AKI during COVID-19 infection

NCT04459975 on Occurrence of Acurate Kidney Injury During Intensive Care Unit Abnormalities of Urinary Analysis Other: Non interventional study
MeSH:Acute Kidney Injury Wounds and Injuries
HPO:Acute kidney injury

Primary Outcomes

Description: AKI will be defined according with KDIGO guidelines: increase in creatinine of more than 1,5 fold compared to baseline Severe CVOID-19 infection is defined as 1/ confirm COVID-19 infection (by TDM and/or qRT-PCR) 2/ Requirement of ICU support during more than 72h

Measure: Primary endpoint is the incidence, the severity and the mortality associated with AKI during COVID-19 severe infection

Time: 7 months

17 SARS-CoV2 Pediatric Acute Kidney Injury Registry and Collaborative

This study is an observational registry of children with or suspected to have SARS CoV2 (COVID-19) admitted to pediatric intensive care units (PICU). This registry will help describe the prevalence, rate and severity of acute kidney injury (AKI) in children with Severe Acute Respiratory Syndrome Coronavirus-2(SARS CoV2) across the world. The registry will be developed using a point prevalence methodology and then full retrospective review. Once a week, from April through June 2020, data collection will occur in "real-time" to estimate a weekly point prevalence of AKI and renal replacement therapy (RRT). The operational definition of "patients under investigation" (PUIs) will be used to identify the denominator of patients to be studied. The PUIs will be cohorted into SARS CoV2 test positive, test negative, test pending, or test unavailable. The primary aim of this study is to deliver a global, objective data driven analysis of the burden of AKI in virus positive patients or patients under investigation (PUI) who are admitted to the pediatric intensive care unit.

NCT04466306 Acute Kidney Injury COVID
MeSH:Acute Kidney Injury Wounds and Injuries
HPO:Acute kidney injury

Primary Outcomes

Description: Kidney Disease Improving Global Outcomes (KDIGO) Staged AKI by serum creatinine or urine output

Measure: Acute Kidney Injury (AKI)

Time: 14 days

Secondary Outcomes

Description: Survival to ICU discharge or Day 14

Measure: Survival

Time: 14 days

Description: The use of extracorporeal membrane oxygenation (ECMO) and/or renal replacement therapy

Measure: Rate of Extracorporeal Therapy Requirement

Time: 14 days

Description: >20% fluid overload as defined as the net fluid balance since ICU admission (in liters) divided by ICU admission weight

Measure: Fluid overload

Time: Day of Enrollment

Description: The exposure of enrolled patients to known nephrotoxic medications, including diuretics

Measure: Rate of nephrotoxic medication exposure

Time: Day of Enrollment


HPO Nodes